🔹 Revenue: $32.65B (Est. $32.00B) 🟢
🔹 EPS (Adj): $3.24 (Est. $2.83) 🟢
🔹 Insurance Segment Benefit Ratio: 91.1% (in line with “just above 91%” expectation)
Affirmed FY’25 Guidance
🔹 EPS (Adjusted): ~$17.00 (Est. $17.04) 🔴
🔹 Insurance Segment Benefit Ratio: 90.1%–90.5%;
🔹 Medicare Advantage Membership: ~(425,000) decline; Improved vs prior guide (up to 500,000 decline)
Segment:
🔹 CenterWell Primary Care: +56,600 patients (~+15% vs 12/31/24)
🔹 CenterWell Pharmacy: continued growth across payor-agnostic offerings; stronger Specialty volumes and DTC growth
🔹 Medicaid & Duals: prepping for Jan 1, 2026 launches (MI HIDE SNP, IL FIDE) and SC duals carve-in
Management Commentary
🔸 “Our strategy of putting the consumer at the heart of everything we do is working, with solid year-to-date performance and strong momentum heading into the Annual Election Period.” – CEO Jim Rechtin